(Q48006853)

7 February 2018

title

Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis (English)

1 reference

7 February 2018

1 reference

Mitchell Levy

1

1 reference

7 February 2018

Marcel Levi

2

1 reference

7 February 2018

Mark D Williams

3

1 reference

7 February 2018

Massimo Antonelli

4

1 reference

7 February 2018

Dazhe Wang

5

1 reference

7 February 2018

Mariano Alejandro Mignini

6

1 reference

7 February 2018

publication date

15 April 2009

1 reference

7 February 2018

published in

Intensive Care Medicine

1 reference

7 February 2018

volume

35

1 reference

7 February 2018

issue

7

1 reference

7 February 2018

page(s)

1196-1203

1 reference

7 February 2018

A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00134-009-1483-7

Drotrecogin alfa (activated): real-life use and outcomes for the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-009-1483-7

Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-009-1483-7

Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-009-1483-7

Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-009-1483-7

Clinical practice. Heparin-induced thrombocytopenia

21 January 2018

1 reference

12 December 2020

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)

1 reference

12 December 2020

Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy

1 reference

12 December 2020

Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors

1 reference

12 December 2020

Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential

1 reference

12 December 2020

Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin

1 reference

12 December 2020

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

1 reference

12 December 2020

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

12 December 2020

Efficacy of deep venous thrombosis prophylaxis in the medical intensive care unit.

1 reference

12 December 2020

Statistical methods in cancer research. Volume I - The analysis of case-control studies.

1 reference

12 December 2020

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

1 reference

12 December 2020

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey

1 reference

12 December 2020

Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis

1 reference

12 December 2020

Results of severe sepsis treatment program using recombinant human activated protein C in Poland

1 reference

12 December 2020

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

1 reference

12 December 2020

Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes

1 reference

12 December 2020

Activated protein C and ischemic stroke

1 reference

12 December 2020

Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-

1 reference

12 December 2020

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

12 December 2020

Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppressio

1 reference

12 December 2020

10.1007/S00134-009-1483-7

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018